The luminal B subtype has aggressive clinical behavior, with a prognosis similar to that of the HER2-enriched and basal-like groups and a lower sensitivity to endocrine treatment compared with luminal A ER+ breast cancer (58). This evidence concerns the gene ESR1 and breast carcinoma.